ClinicalTrials.gg
RecruitingNCT04969731Updated Nov 22, 2021

Safety and Efficacy of Immuncell-LC With Gemcitabine in Resectable Pancreatic Cancer

A Phase 3 interventional study of Immuncell-LC and Gemcitabine in Pancreatic Ductal Adenocarcinoma, sponsored by GC Cell Corporation. Recruiting at 1 site in Korea, Republic of. Open to participants aged 19 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-11-22.

Sponsored by GC Cell Corporation · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2021; still recruiting 5 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
408
Allocation
Randomized
Ages
19 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 198 studies in Pancreatic Neoplasms with a site in Korea, Republic of — 43 open to participants now, 63 under way, 10 of them phase 3. Pancreatic Neoplasms · Korea, Republic of.

Planned enrollment
26th of 164
408 · median 100
Started
2021
with 20 others
Phase 3
22 of 198
6 open now
Primary completion
2026-12
later than 24 of 62 live
Registered
140th of 198
by date

Among the 198 studies in Pancreatic Neoplasms with a site in Korea, Republic of, this one is the 26th largest by planned enrollment of the 164 interventional ones that give a count, is one of 21 that started in 2021, is one of 22 in phase 3, reaches primary completion later than 24 of the 62 other live ones, and was the 140th registered.

Pancreatic Neoplasms

3,903 studies on the registry are indexed under Pancreatic Neoplasms; 1,005 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

43 of the 198 studies in Pancreatic Neoplasms with a site in Korea, Republic of are open now. Recruiting first, the newest first:

38 more — sign in →

All 43 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 743 Pancreatic Neoplasms studies recruiting now, 476 (64%) set no upper age limit and 153 (21%) stop at 75 or younger; 40 take children under 18; 60 take healthy volunteers.

This study: 19 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 198 studies in Pancreatic Neoplasms with a site in Korea, Republic of, or all of them as a file.
02

Study summary

PURPOSE: This phase III clinical trial evaluates the efficacy and safety of adjuvant Immuncell-LC therapy combined with gemcitabine versus adjuvant gemcitabine single therapy after R0 or R1 resection in patients with pancreatic ductal adenocarcinoma.

Read the detailed description

Open-label, Randomized, Multi-center, Parallel, Phase III Clinical Trial

03

Conditions studied

  • Pancreatic Ductal Adenocarcinoma

Keywords

  • Adjuvant Therapy
  • Immuncell-LC
  • Gemcitabine
  • ILC-P3-PAN
  • Pancreatic Cancer
04

Who can participate

Ages eligible
19 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age >/=20 years old, \</=80 years old.
  2. or cytologically confirmed pancreatic ductal adenocarcinoma that fulfill the following requirements:

    • Participants have undergone a radical full resection (R0) or boundary resection (R1) operation and has elapsed at least two weeks after the resection based on the baseline, up to 12 weeks.
    • Noncancerous ascites.
    • No evidence of distant (such as liver, peritoneum)
    • No evidence of distant metastasis in other distant abdominal or extra-abdominal organs
    • Scheduled to be given gemcitabine alone as postoperative chemotherapy
  3. -performance status (ECOG-PS) 0 - 2
  4. is at least 12 weeks.
  5. Adequate organ and marrow function at the screening and baseline as defined below:

    • ≥ 1,500/μL
    • level ≥ 9 g/dL
    • count ≥ 100,000/μL
    • BUN, serum creatinine ≤ 1.5 × institutional (ULN)
    • , ALT ≤ 2.5 × institutional upper limit of normal (ULN)
    • PT (), activated partial thromboplastin time (aPTT) ≤ 1.5 × institutional upper limit of normal (ULN)
  6. Ability to understand and the willingness to sign a written document.

Exclusion criteria

Exclusion Criteria:

  1. Received anticancer therapy including chemotherapy, biological therapy, immunotherapy, hormone therapy, radiation therapy, and other anti-cancer treatments. Note: therapy for pancreatic cancer is allowed.
  2. identified in the pancreas after surgery.
  3. Known history at the screening as defined below.

    • Confirmed cases of acquired immunodeficiency, which can be exacerbated by immunotherapy.
    • History of diseases that can be exacerbated by immunotherapy. (e.g. rheumatoid arthritis, systemic lupus, vascular inflammation, multiple sclerosis, adolescent-induced insulin-dependent diabetes, T-cell lymphoma, etc.)
    • Active or virus infection confirmed.
    • (HIV) antibody test results are positive during screening
    • History of malignant tumors other than pancreatic cancer within five years of screening. Note: skin basal cell cancer/squamous cell cancer, local prostate cancer, thyroid papillary cancer or cervical epithelial cancer can be participated even if 5 years have passed since successful treatment.
  4. Known associated disease at the screening as defined below.

    • Severe nephropathy: estimated (eGFR)‡ \<30 mL/min/1.73 m2
    • Chest X-ray shows epileptic pneumonia or pulmonary fibrosis with clear, clinical symptoms.
    • Severe infections or other uncontrolled active infectious diseases requiring the administration of antibiotics, antibacterial drugs, antifungal drugs, antiviral drugs, etc. that may affect safety and validity evaluation during clinical trials, as determined by the tester.
    • Holder of thromboembolic disease or bleeding diatheses
    • Those who are deemed unfit to participate in clinical trials because they are not controlled or require treatment (e.g., heart disease, pulmonary dysfunction, renal dysfunction, low blood pressure, hypertension, bone marrow inhibition, liver , hepatitis, history of alcoholism, myocardial infarction, etc.)
  5. Received Immuncell-LC, Natural Killer (NK) cell therapy or other cell therapy drugs within three years prior to screening.
  6. Anaphylaxis to the main ingredient or sub-brothers of Immuncell-LC or Gemcitabine
  7. Patients who cannot collect blood for manufacturing Immuncell-LC depending on the investigator's judgment.
  8. Pregnant or lactating women
  9. Fertility women and men who are not willing to use appropriate from screening to 24 weeks after final administration of Immuncell-LC and/or Gemgitabine
  10. Received or applied with another products or investigational device within 4 weeks prior to signing a written document.
  11. Patients who are inappropriate or impossible to participate in the trial due to non-recovery of resection or prior chemotherapy depending on the investigator's judgment.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
408 participants (estimated)

Study arms

  • Experimental
    Immuncell-LC/Gemcitabine

    Patients will receive 6 cycles Gemcitabine (1000 mg/m2 on Days 1, 8, 15, 28-day a cycle) and Immuncell-LC 16 times during 60 weeks (4 treatments once a week, followed by 4 treatments every other week, then 4 treatments every 4 weeks, and finally 4 treatments every 8 weeks)

    Drug: Immuncell-LC · Drug: Gemcitabine

  • Active comparator
    Gemcitabine

    Patients will receive 6 cycles Gemcitabine alone (1000 mg/m2 on Days 1, 8, 15, 28-day a cycle)

    Drug: Gemcitabine

Interventions

06

What researchers measure

Primary outcomes

  1. Recurrence free survival (RFS) by independent review

    Recurrence free survival is defined as the time from randomization to the date of the recurrence confirmed by independent reviewer

    Time frame: Up to approximately 36 months after Last Patient In

Secondary outcomes

  1. Overall survival (OS)

    Overall survival is defined as the time from randomization to death due to any cause.

    Time frame: Up to approximately 36 months after Last Patient In

  2. Recurrence free survival (RFS) by investigator

    Recurrence free survival is defined as the time from randomization to the date of the recurrence confirmed by investigator

    Time frame: Up to approximately 36 months after Last Patient In

  3. Carbohydrate antigen 19-9 level

    Carbohydrate antigen 19-9 level

    Time frame: Up to approximately 36 months after Last Patient In

  4. Quality of Life (QoL) EORTC QLQ-C30

    The QLQ-C30 is composed of both multi-item scales and single-item measures. These include five functional scales, three symptom scales, a global health status / QoL scale, and six single items. Each of the multi-item scales includes a different set of items - no item occurs in more than one scale. All of the scales and single-item measures range in score from 0 to 100. A higher score represents a higher ("better") level of functioning, or a higher ("worse") level of symptoms.

    Time frame: Up to approximately 36 months after Last Patient In

  5. Quality of Life (QoL) EORTC QLQ-PAN26

    The module comprises 26 questions assessing pain, dietary changes, jaundice, altered bowel habit, emotional problems related to pancreatic cancer, and other symptoms (cachexia, indigestion, flatulence, dry mouth, taste changes). The answers range is the following: not at all - 1 point, a little - 2 points, quite a bit - 3 points, very much - 4 points. Minimum score is 26, maximum is 106. The higher total score represents the worse quality of life.

    Time frame: Up to approximately 36 months after Last Patient In

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2021 (actual). Primary completion is estimated for Dec 2026, 63 months after the start.

Of 84 phase 3 interventional studies under Pancreatic Neoplasms, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 77. This study's planned 63 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 6, 2021
First posted
Jul 21, 2021
StartActual
Sep 7, 2021
Primary completionEst.
Dec 2026
CompletionEst.
Jun 2027
Last update
Nov 22, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 22, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04969731
Lead sponsor
GC Cell Corporation
Responsible party
Sponsor
First posted
Jul 21, 2021
Start date
Sep 7, 2021
Primary completion
Dec 2026 (estimated)
Completion
Jun 2027 (estimated)
Last update
Nov 22, 2021

Study contacts

Sang Hyub Lee
principal investigator · Seoul National University Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Autologous Cytokine-induced Killer Cells

Start the discussion